Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$139.02 USD

139.02
2,616,684

+10.04 (7.78%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

Illumina (ILMN) is currently keeping well with its goals to strengthen foothold in the multi-billion gene sequencing market.

Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

Illumina (ILMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Illumina (ILMN) closed at $309.84, marking a +0.21% move from the previous day.

LGND vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LGND vs. ILMN: Which Stock Is the Better Value Option?

Align Technology-Benco Dental Deal to Expand iTero Reach

by Zacks Equity Research

Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.

GNC Holdings to Expand Portfolio With Alani Nutrition Deal

by Zacks Equity Research

With Alani Nutrition being a women-focused supplement brand, it is believed that the partnership might help GNC Holdings (GNC) widen its customer base.

Tandem's Global Growth a Boost, Operating Losses a Bane

by Zacks Equity Research

Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.

GNC Forms Joint Venture With IVC to Improve Cost Efficiency

by Zacks Equity Research

The joint venture is set to manufacture the products produced by GNC Holdings' (GNC) Nutra manufacturing facility.

Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now

by Zacks Equity Research

Hologic's (HOLX) management is impressed with continued growth in the core Molecular Diagnostics sub-segment.

Hologic (HOLX) Receives Global Nods for Omni Hysteroscope

by Zacks Equity Research

Hologic's (HOLX) receipt of approvals for Omni Hysteroscope in Canada and Europe is expected to boost the GYN Surgical arm.

Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

by Zacks Equity Research

Synergies from Alere consolidation in the form of revenues from Abbott's (ABT) Rapid Diagnostics business have been driving growth.

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

Illumina (ILMN) continues to gain on solid international business.

Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y

by Zacks Equity Research

Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.

CBM or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CBM vs. ILMN: Which Stock Is the Better Value Option?

Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark

by Zacks Equity Research

Illumina's (ILMN) Q4 figures show a sturdy uptick in sequencing consumable revenues.

Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

by Zacks Equity Research

We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.

Thermo Fisher (TMO) Down on Business Divestment Declaration

by Zacks Equity Research

Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.

Cerner (CERN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Cerner's (CERN) fourth-quarter 2018 results are likely to be hurt by year-over-year decline in bookings; Q4 guidance promising.

Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?

by Zacks Equity Research

McKesson (MCK) expects to gain from solid segmental performances in third-quarter fiscal 2019.

Will Lower Revenues Dampen Juniper's (JNPR) Q4 Earnings?

by Zacks Equity Research

Juniper (JNPR) is likely to report lower year-over-year revenues in Q4 due to challenges in the market, particularly within the cloud vertical.

AmerisourceBergen (ABC) Q1 Earnings: What's in the Cards?

by Zacks Equity Research

AmerisourceBergen's (ABC) first-quarter fiscal 2019 results are likely to gain from its core Pharmaceutical Distribution business unit.

Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

by Zacks Equity Research

Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets bode well for Tandem Diabetes (TNDM).

What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) expected to see consistent performance by Surgical Structural Heart and Critical Care segments in Q4.

Will Top-Line Growth Support Corning's (GLW) Q4 Earnings?

by Zacks Equity Research

Corning (GLW) is likely to report higher year-over-year revenues in fourth-quarter 2018 on the back of healthy growth dynamics.

Will GPU Product Introduction Benefit AMD's Q4 Earnings?

by Zacks Equity Research

AMD Q4 results to benefit from GPU Product Rollouts & Partnerships